1-15 of 281
Advances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents
CME/CEAdvances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents
Guy Young, MD
Annette von Drygalski, MD, PharmD, RMSK
Steven Pipe, MD
Robert Sidonio Jr, MD, MSc
Living With Systemic Mastocytosis: Bridging Clinical Decisions and Patient Realities
CME/CELiving With Systemic Mastocytosis: Bridging Clinical Decisions and Patient Realities
Cem Akin, MD, PhD
Precision Strikes in AML: Navigating the Evolving Landscape of Targeted Therapies
CME/CEPrecision Strikes in AML: Navigating the Evolving Landscape of Targeted Therapies
Harry Erba, MD, PhD
Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
CME/CENavigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
Mariana C. Castells, MD, PhD
Tsewang Tashi, MD
The Future of HNSCC: Aligning Teams, Transforming Care
CME/CEThe Future of HNSCC: Aligning Teams, Transforming Care
Ravindra Uppaluri, MD, PhD
Nancy Lee, MD, FASTRO
- advertisement
Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
CME/CEChairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
Benjamin Levy, MD
Targeting B7-H3 in ES-SCLC: Advancing Targeted Therapy Through Evidence-Based Innovation and Multidisciplinary Care
CME/CETargeting B7-H3 in ES-SCLC: Advancing Targeted Therapy Through Evidence-Based Innovation and Multidisciplinary Care
Taofeek K. Owonikoko, MD, PhD
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
CME/CEAdvancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
María-Victoria Mateos, MD, PhD
Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
CME/CENavigating Treatment Sequencing After Frontline Treatment Failure in CLL
Jennifer R. Brown, MD, PhD
William Mencia, MD, FACEHP
Double-Class Refractory CLL in Community Practice: Current and Future Management
CME/CEDouble-Class Refractory CLL in Community Practice: Current and Future Management
John C. Byrd, MD
William Mencia, MD, FACEHP
William Wierda, MD, PhD
Matthew S. Davids, MD, MMSc
- advertisement
Progress in Breast Cancer Care: Translating SABCS Data Into Practice
CME/CEProgress in Breast Cancer Care: Translating SABCS Data Into Practice
Charles E. Geyer Jr., MD, FACP
Komal Jhaveri, MD, FACP
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
CME/CEAdvancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Cristina Rodriguez, MD
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
CME/CEFrom Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
María-Victoria Mateos, MD, PhD
Luciano Costa, M.D., Ph.D.
